What is Neonatal Abstinence Syndrome?
Neonatal Abstinence Syndrome (NAS) is a group of withdrawal symptoms that occur in newborns who were exposed to addictive substances, most commonly opioids, during pregnancy. When a pregnant woman uses opioids such as heroin, methadone, buprenorphine, or prescription painkillers, these drugs cross the placental barrier and the fetus becomes physically dependent on the substance. After birth, the sudden discontinuation of the drug supply triggers withdrawal symptoms in the neonate.
NAS has become a significant public health concern in recent decades, with incidence rising dramatically alongside the opioid epidemic. In the United States, NAS affects approximately 7 out of every 1,000 hospital births, with incidence rates increasing fivefold between 2004 and 2014. The condition places substantial burden on neonatal intensive care units (NICUs), with affected infants requiring an average hospital stay of 17 to 23 days compared to 2 to 3 days for healthy newborns.
Symptoms of NAS typically appear within 24 to 72 hours after birth for short-acting opioids and within 48 to 72 hours (sometimes up to 5 to 7 days) for longer-acting opioids like methadone. The severity and duration of withdrawal depend on the type and amount of substance used, timing of last maternal dose, gestational age at birth, and individual metabolic differences between neonates.
The Finnegan Scoring System
The Finnegan Neonatal Abstinence Scoring Tool was developed by Dr. Loretta P. Finnegan in the 1970s at Thomas Jefferson University Hospital in Philadelphia. It is the most widely used standardized assessment tool for evaluating and managing NAS worldwide. The tool consists of 16 clinical signs grouped into three categories: central nervous system (CNS) disturbances, gastrointestinal (GI) disturbances, and metabolic/vasomotor/respiratory disturbances.
Each sign is assigned a numerical score based on severity, and the individual scores are summed to produce a total NAS score. This total score is then used to guide clinical decisions about the need for pharmacological treatment. The scoring system is designed to be administered by trained nursing staff at regular intervals, typically every 3 to 4 hours, to track symptom progression and treatment response.
The original Finnegan tool has been modified by various institutions over the years, resulting in several versions including the Modified Finnegan Neonatal Abstinence Scoring Tool. While the core assessment items remain similar, some modifications simplify the scoring process or adjust point values. This calculator uses the standard Finnegan scoring system.
How to Score
Accurate scoring requires careful clinical observation by trained personnel. Each assessment should be performed at the bedside during routine care interactions. Key principles for accurate scoring include:
- Score after feeding: Assessment should ideally occur before feeding (to observe hunger cues) and after feeding (to observe sleep patterns and GI symptoms)
- Score what you observe: Only score signs that are actually observed during the assessment period, not historical or reported symptoms
- Assess in a quiet environment: Distinguish between symptoms that occur when the infant is disturbed versus undisturbed, as this affects scoring (especially for tremors)
- Use consistent technique: All staff should be trained on the same scoring methodology to minimize inter-rater variability
- Score at regular intervals: Assessments should be performed every 3 to 4 hours to capture symptom patterns over time
| Category | Items Assessed | Maximum Points |
|---|---|---|
| CNS Disturbances | Cry, sleep, Moro reflex, tremors, muscle tone, excoriation, myoclonic jerks, seizures | 21 |
| GI Disturbances | Feeding, vomiting, stools | 8 |
| Metabolic/Respiratory | Temperature, yawning, sneezing, nasal stuffiness, respiratory rate | 7 |
| Total Maximum | 36 |
Score Interpretation
| Total NAS Score | Interpretation | Action |
|---|---|---|
| < 8 | Mild withdrawal or no withdrawal | Continue supportive care and monitoring; pharmacological treatment not indicated |
| 8 – 12 | Moderate withdrawal | Increase monitoring frequency; consider non-pharmacological interventions; initiate pharmacotherapy if scores remain elevated |
| > 12 | Severe withdrawal | Pharmacological treatment indicated; initiate first-line medication protocol |
The threshold for initiating pharmacological treatment is typically three consecutive scores of 8 or greater, or two consecutive scores of 12 or greater. However, institutional protocols may vary, and clinical judgment should always be applied alongside scoring results. Some institutions use a single score threshold while others require sustained elevated scores before initiating treatment.
When to Treat
Management of NAS begins with non-pharmacological interventions for all affected infants, regardless of score. These supportive measures include:
- Swaddling: Firm swaddling provides comfort and reduces sensory stimulation
- Low-stimulation environment: Dim lighting, minimal noise, and limited handling
- Frequent small feedings: On-demand feeding with high-calorie formula if needed to compensate for increased metabolic demands
- Skin-to-skin contact: Kangaroo care has been shown to reduce NAS severity
- Breastfeeding: Encouraged when not contraindicated, as small amounts of opioids in breast milk may ease withdrawal
- Rooming-in: Keeping mother and infant together reduces NAS severity and length of stay
Pharmacological treatment is considered when NAS scores consistently exceed 8 despite optimal non-pharmacological management, or when complications such as seizures, dehydration from vomiting or diarrhea, poor weight gain, or high fevers occur.
Pharmacological Treatment Options
When pharmacological intervention is necessary, the following medications are commonly used:
- Morphine sulfate: The most commonly used first-line agent. It is administered orally in a weight-based or symptom-based dosing protocol. Morphine provides targeted opioid replacement therapy and allows for gradual weaning as withdrawal symptoms improve
- Methadone: An alternative first-line agent with a longer half-life than morphine. Some institutions prefer methadone for its less frequent dosing schedule (every 6 to 12 hours versus every 3 to 4 hours for morphine)
- Buprenorphine: A partial opioid agonist that has shown promise in clinical trials. Sublingual buprenorphine may reduce treatment duration compared to morphine, with some studies showing a 40% reduction in length of treatment
- Clonidine: An alpha-2 adrenergic agonist used as adjunctive therapy when opioid monotherapy is insufficient. Clonidine addresses autonomic symptoms such as tachycardia, hypertension, and sweating
- Phenobarbital: Used as second-line therapy for refractory cases or for non-opioid-related NAS (e.g., benzodiazepine exposure). It is being used less frequently due to concerns about neurodevelopmental effects
Long-Term Effects
Research on the long-term outcomes of infants affected by NAS is ongoing and reveals several areas of concern:
- Neurodevelopmental outcomes: Studies suggest that children with a history of NAS may be at higher risk for developmental delays, learning difficulties, and behavioral problems. However, separating the effects of prenatal drug exposure from environmental factors (such as poverty, unstable home environments, and parenting challenges) remains difficult
- Growth: Some studies have found lower birth weight and head circumference in NAS-affected infants, though catch-up growth generally occurs by 12 to 24 months of age with appropriate nutrition and care
- Vision and hearing: Prenatal opioid exposure has been associated with strabismus (crossed eyes) and potential hearing abnormalities, though the evidence is mixed
- Behavioral health: Emerging evidence suggests possible associations between NAS and attention deficit hyperactivity disorder (ADHD), conduct disorders, and anxiety in childhood and adolescence
- Cognitive function: While severe cognitive impairment is uncommon, subtle differences in executive function, processing speed, and academic achievement have been reported in school-age follow-up studies
It is important to emphasize that many children who experienced NAS develop normally, especially when provided with stable, nurturing environments and early intervention services when needed. Comprehensive follow-up care, including developmental screening and family support, is essential for optimizing outcomes.
Frequently Asked Questions
How often should the Finnegan NAS score be assessed?
The NAS score should be assessed every 3 to 4 hours, ideally 30 minutes to 2 hours after feeding. Scoring should begin within the first 2 hours of life for infants at risk and continue for at least 72 to 96 hours after birth (or longer for long-acting opioid exposure). Once pharmacological treatment is started, scoring continues to guide dose adjustments and weaning.
Can NAS occur from medications other than opioids?
Yes, NAS can occur from prenatal exposure to various substances including benzodiazepines, barbiturates, selective serotonin reuptake inhibitors (SSRIs), and alcohol. However, the Finnegan scoring tool was specifically designed for opioid withdrawal and may not capture all symptoms associated with withdrawal from other substances. Withdrawal from SSRIs, for example, may present differently with symptoms such as jitteriness, irritability, and sleep disturbances.
Is the Finnegan score the only NAS assessment tool available?
No, several alternative tools exist. The Eat, Sleep, Console (ESC) approach is increasingly adopted as a function-based assessment that focuses on the infant's ability to eat adequately, sleep sufficiently, and be consoled. Studies have shown that the ESC approach can significantly reduce pharmacological treatment rates and shorten hospital stays without compromising infant safety. Other tools include the Lipsitz Neonatal Drug Withdrawal Scoring System and the Neonatal Narcotic Withdrawal Index (NNWI).
How long does NAS typically last?
The duration of NAS varies significantly depending on the substance and severity of exposure. For short-acting opioids like heroin, acute withdrawal typically resolves within 1 to 2 weeks. For longer-acting opioids like methadone, withdrawal symptoms may persist for 2 to 6 weeks. Infants requiring pharmacological treatment typically have hospital stays averaging 17 to 23 days, with some requiring up to 6 to 8 weeks of treatment.
Does breastfeeding help reduce NAS severity?
Yes, breastfeeding has been shown to reduce NAS severity and the need for pharmacological treatment, provided the mother is in a stable treatment program (e.g., methadone or buprenorphine maintenance), is not using illicit substances, and is HIV-negative. The small amounts of opioids transferred through breast milk may provide a gentle weaning effect. Breastfed infants with NAS have been found to have lower NAS scores, shorter hospital stays, and reduced need for medication compared to formula-fed infants.